【摘要】 目的比较紫杉醇+卡铂与紫杉醇+顺铂治疗晚期卵巢癌的疗效和毒性。方法62例初治晚期卵巢癌患者随机分为紫杉醇+卡铂组(A组)30例和紫杉醇+顺铂组(B组)32例,化疗6~8周期后评价临床缓解率和药物毒性。结果A组有效率为73.3%,平均生存时间35个月;B组有效率71.9%,平均生存时间32个月,两组疗效和平均生存时间差异无显著性(P>0.05)。胃肠道反应、肾毒性和肌肉关节疼痛A组较B组轻(P<0.05)。结论紫杉醇+卡铂治疗晚期卵巢癌有效率不低于紫杉醇+顺铂,但毒性反应明显减轻,从临床的实用性和便利性考虑,更容易为临床医师和患者接受,特别适用于老年患者及对顺铂耐受性差的患者。更多还原

【Abstract】 Objective To evaluate the efficacy and toxicity of paclitaxel plus carboplatin and paclitaxel plus cisplatin in the treatment of advanced-stage ovarian cancer.Methods Sixty-two untreated patients with advanced-stageovarian cancers were randomized to paclitaxel plus carboplatin group(group A,n=30)and paclitaxel plus cisplatin group(group B,n=32).Efficacy and toxicity were assessed after 6-8 cycles of treatment for each patient.Results The response rate(RR)in group A was 73.3% and in group B was(71.9%).The mean survival time was 35 months in group A and 32 months in group B.There was no significant difference of RR and mean survival time between groups A and B(P>0.05).Gastrointestinal reaction,myalgia or arthralgia and renal dysfunction in group A was millder than those in group B(P<0.05).Conclusion There is no significant difference between paclitaxel plus carboplatin and paclitaxel plus cisplatin.But the toxicity is milder with paclitaxel plus carboplatin than with paclitaxel plus cisplatin.Considering clinical practicality and convenience,paclitaxel plus carboplatin is easy to be accepted by both patients and clinicans,and is especially suitable for the elderly and the patients with low tolerance to cisplatin.更多还原